Is it safe?
Can ADMA take a bad year?
ADMA Biologics, Inc. carries $59M of net debt at 0.26× EBITDA: a load its earnings can carry.
$59M
Net debt · as at Q1 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.26×
Net debt / EBITDA
- Altman Z-score
- 10.48
Altman Z-score · safe zone, above 3
- Interest cover
- 29.7×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2026
- $197M
- Cash and short-term investments
- $138M
- Net debt
- $59M
- EBITDA, trailing twelve months
- $223M
- Operating profit, trailing twelve months
- $215M
- Debt / equity
- 0.50×
- Total debt / EBITDA
- 0.88×
- Annualised volatilitytwo years of daily moves
- 62%
- Worst drawdown on file
- −86%
- Below its 52-week high
- −53%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.